Carlyle Group connected to $4.3 billion PPD buy
This article was originally published in Scrip
After weeks of speculation about a potential sale the Washington DC-based private equity firm, Carlyle Group, the previous owner of CRO PRA International, has been linked to the CRO PPD for a buy thought to be worth $4.3 billion.
You may also be interested in...
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"